7th

Urologic Oncology:Advances in Clinical Practice

November 2–3, 2012MD Anderson, Dan L. Duncan BuildingFloor 8 Conference Center, 1155 Pressler, Houston, Texas

Nursing Session – November 2, 2012Urologic Oncology:Nursing Advances in Clinical PracticeMD Anderson, Mays Clinic, ACB1.23451220 Holcombe Boulevard, Houston, Texas

FocusThe 7th Urologic Oncology Conference will focus on the diagnosis, treatment, clinical advances, and controversies in localized and advanced cancers of the bladder, prostate and kidney.

Educational ObjectivesAfter attending the conference, participants should be able to• illustrateandimplementclinicaladvancesinthediagnosisandevaluationofbladder,prostate,andkidneycancers(knowledge, competence, performance, patient outcomes);

• illustrateandimplementclinicaladvancesinthetreatmentapproachtolocalizedandlocallyadvancedbladder,prostateandkidneycancers,includingtheroleofminimallyinvasiveroboticsurgery(knowledge, competence, performance, patient outcomes);

• illustrateandimplementclinicaladvancesinthetreatmentapproachtometastaticbladder,prostateandkidneycancers(knowledge, competence, performance, patient outcomes);

• identifycontemporarycontroversiesinthemanagementofbladder,prostateandkidneycancers(knowledge).

Educational MethodsLectures – Case Presentations – Panel Discussions – Audience Response System – Question and Discussion Sessions

7th Urologic Oncology: Advances in Clinical PracticeNovember 2-3, 2012

Nursing Session – November 2, 2012Urologic Oncology: Nursing Advances in Clinical Practice

EvaluationAcourseevaluationformwillprovideparticipantswiththeopportunitytocommentonthevalueoftheprogramcontenttotheirpracticedecisions,performanceimprovementactivities,orpossibleimpactonpatienthealthstatus.Participantswillalsohavetheopportunitytocommentonanyperceivedcommercialbiasinthepresentationsaswellastoidentifyfutureeducationaltopics.

Accreditation/Credit DesignationPhysiciansTheUniversityofTexasMDAndersonCancerCenterisaccreditedbytheAccreditationCouncilforContinuingMedicalEducationtoprovidecontinuingmedicaleducationforphysicians.

TheUniversityofTexasMDAndersonCancerCenterdesignatesthisliveactivityforamaximumof13.25 AMA PRA Category 1 CreditsTM.Physiciansshouldclaimonlythecreditcommensuratewiththeextentoftheirparticipationintheactivity.

Target AudienceThis conference should be of value to urologists, medical oncologists, nurses, nurse practitioners, and physician assistants.

CME Certificates and Attendance Verification CertificatesCertificatesawardingAMA PRA Category 1 CreditTMorcertificatesdocumentingattendancewillbedistributedtoparticipantsastheydepartthesymposium.ToobtainaCMEcertificate,physiciansmustsubmitacompletedevaluationquestionnaireandaCME Verification Form.

Uponrequest,arecordofattendance(certificate)willbeprovidedon-sitetootherhealthcareprofessionalsforrequestingcreditsinaccordancewithstatenursingboards,specialtysocieties,orotherprofessionalassociations.

Christopher G. Wood, MDProgram Co-ChairmanProfessor and Vice ChairmanUrology

Nizar M. Tannir, MDProgram Co-ChairmanAssociate Professor and Vice ChairmanGenitourinary Medical Oncology

Seungtaek Choi, MDAssistant ProfessorRadiation Oncology

Gloria CurtisSenior Administrative AssistantGenitourinary Medical Oncology

John W. Davis, MDAssistant ProfessorUrology

Silvestina DeCoteau, RN, MSN, NEA-BCNursing Program Co-ChairmanAssociate Director of Clinical NursingNursing

Carol FourtuniaSenior Administrative AssistantUrology

Lisa G. Green, MSN, RN, AOCNNurse EducatorNursing

Deborah Hooker, RN, MSN, BC, ACNPNursing Program Co-ChairmanAdvanced Practice NurseUrology

Colleen HubonaDirector, Multidisciplinary Programs and ProjectsProgram Center – Genitourinary

Jay B. Shah, MDAssistant ProfessorUrology

Arlene Siefker-Radtke, MDAssociate ProfessorGenitourinary Medical Oncology

Judi Williams, BSSenior Conference CoordinatorCME/Conference Management

Conference Chairmen

Conference Committee

MDAndersonOrganizingCommittee

Friday,November2,2012Noon RegistrationandGeneralSessionLunch

12:45pm Welcome and Opening Remarks ChristopherG.Wood,MD;andNizarM.Tannir,MD

SESSION I: UROTHELIAL CANCER Session Chairs: Jay B. Shah, MD; and Arlene Siefker-Radtke, MD

Superficial DiseaseModerator: Jay B. Shah, MD

1:00 Basics of Superficial Disease and CIS: The University of Texas MD Anderson Cancer Center Treatment Algorithm

JayB.Shah,MD 1:10 Novel Approaches to Localized Bladder Cancer ColinDinney,MD

1:20 Controversy: T1 High Grade Disease: BCG vs. Cystectomy

BCG is the Best Therapy AshishKamat,MD

Immediate Cystectomy is the Best Therapy ColinDinney,MD

Upper Tract DiseaseModerator: Arlene Siefker-Radtke, MD1:40 Treatment of Superficial Upper Tract Transitional

Cell Carcinoma SurenaMatin,MD

1:50 Role for Neoadjuvant Therapy and LND for Upper Tract Transitional Cell Carcinoma

ArleneSiefker-Radtke,MD

ProgramUrologic Oncology: Advances in Clinical Practice

2:00 Case Presentation: Superficial Bladder Cancer and Upper Tract Tumors

Moderator: Jay B. Shah, MD Panelists: Colin Dinney, MD; Ashish Kamat, MD; Surena Matin, MD;

and Arlene Siefker-Radtke, MD

2:30 Questions and Discussion

2:40 Break

Treatment of Advanced Disease Moderator: Arlene Siefker-Radtke, MD

3:00 Robotic Cystectomy with Intracorporal Urinary Diversion JohnW.Davis,MD 3:10 Bladder Replacement Options O.LenaineWestney,MD 3:20 Controversy: Extent of LND Debate

Extended LND is Necessary H.BartonGrossman,MD

Extended LND is Not Necessary JayB.Shah,MD

3:40 Neoadjuvant Chemotherapy – The University of Texas MD Anderson Cancer Center Treatment Paradigm

FarshidDayyani,MD,PhD 3:50 Controversy: Is There a Role for Radiation in the Curative

Management of Bladder Cancer?

Yes, There is a Role AndrewLee,MD,MPH

No, There is Not a Role RandallMillikan,MD,PhD

4:10 Node Positive Urothelial Cancer: “When to Snip, When to Dip” ArleneSiefker-Radtke,MD

4:20 Questions and Discussion

4:30 Break

4:45 Case Presentations in Bladder Cancer Moderator: Arlene Siefker-Radtke, MD Panelists: John W. Davis, MD; Farshid Dayyani, MD, PhD; Colin Dinney, MD;

H. Barton Grossman, MD; Ashish Kamat, MD; Andrew Lee, MD, MPH; John A. Libertino, MD; Randall Millikan, MD, PhD; Jay B. Shah, MD; and O. Lenaine Westney, MD

5:30 Andrew C. von Eschenbach Lecture JohnA.Libertino,MD

6:15pm AdjournandReception

Saturday,November3,2012

7:00am RegistrationandBreakfast

8:00 Welcome and Opening Remarks ChristopherG.Wood,MD;andNizarM.Tannir,MD

8:05 Distinguished Alumnus Presentation WassimKassouf,MD

SESSION II: KIDNEY CANCER Session Chairs: Christopher G. Wood, MD; and Nizar M. Tannir, MDModerator: Christopher G. Wood, MD

Case Presentation74yearoldWMpresentswithincidentalfindingofa3.5cmincidentalrenalmass.Co-morbiditiesincludeHTNandTypeIIDM.

What is the Best Treatment Option?8:30 The Case for Partial Nephrectomy

JoseA.Karam,MD

8:45 The Case for Thermal Ablation KamranAhrar,MD

9:00 The Case for Active Surveillance SurenaMatin,MD

Case Presentation55yearoldWMpresentswithlocallyadvancedrightrenaltumorwithIVCthrombusuptothehepaticveins.Metastaticevaluationisnegative.

What is the Best Treatment Option?9:15 The Role of Adjuvant and Neoadjuvant Therapy The Role of Lymph Node Dissection in the Treatment of

Kidney Cancer ChristopherG.Wood,MD

9:45 Management of IVC Thrombi in Locally Advanced Renal Cell Carcinoma

JohnA.Libertino,MD

10:00 Questions and Discussion

10:10 Break

Moderator: Nizar M. Tannir, MD

Case Presentation47yearoldWFpresentswithlocallyadvancedleftrenalprimaryandbilateralpulmonarymetastases

What is the Best Treatment Option?Controversy: The Role of Cytoreductive Nephrectomy in the Era of Targeted Therapy

10:25 Upfront Cytoreductive Nephrectomy is the Standard of CareJoseA.Karam,MD

10:40 Pre-surgical Therapy is a Better Standard of Care ChristopherG.Wood,MD

10:55 Immunotherapy for Metastatic Renal Cell Carcinoma: Where We Have Been and Where We are Headed

EricJonasch,MD

11:10 Systemic Targeted Therapy in the Treatment of Metastatic Renal Cell Carcinoma: What is the Right Initial Agent, and What To do at Disease Progression?

NizarM.Tannir,MD

11:25 Stereotactic Radiosurgery for Metastatic Renal Cell Carcinoma: What are the Outcomes?

StephenSettle,MD,PhD

11:40 Questions and Discussion: Renal Case Presentations Moderators: Christopher G. Wood, MD; and Nizar M. Tannir, MD

Panelists: Kamran Ahrar, MD; Eric Jonasch, MD; Jose A. Karam, MD; John A. Libertino, MD; and Surena Matin, MD

12:30pm Lunch

SESSION III: PROSTATE CANCER Session Chairs: Seungtaek Choi, MD; and John W. Davis, MDModerator: John W. Davis, MD

1:15 Topic: Screening / Detection for Prostate Cancer Discussants:JohnW.Davis,MD;RobertB.Evans,PA-C;and

WilliamJ.Graber,MD

1:45 Topic: Low Grade / Volume Prostate Cancer – Treatment Options Discussants:BrianF.Chapin,MD;AndrewLee,MD,MPH;VikasKundra,MD,PhD;ThomasPugh,MD;andJohnF.Ward,MD

2:30 Topic: High Risk / Locally Advanced Prostate Cancer – Treatment Options

Discussants:BrianF.Chapin,MD;PaulCorn,MD;andSeanMcGuire,MD,PhD

3:15 Break

3:30 Topic: Lymph Node Positive Prostate Cancer Discussants:BrianF.Chapin,MD;KarenHoffman,MD;and

LancePagliaro,MD

4:00 Topic: Recurrent / Metastatic Disease Discussants:AnaAparicio,MD;BrianF.Chapin,MD;and

SeungtaekChoi,MD

4:45 Case Presentations in Prostate Cancer Moderator: Seungtaek Choi, MD Panelists: Ana Aparicio, MD; Brian F. Chapin, MD; Paul Corn, MD;

John W. Davis, MD; Karen Hoffman, MD; Lance Pagliaro, MD; and John F. Ward, MD

5:30pm Closing Remarks and Adjourn ChristopherG.Wood,MD

Kamran Ahrar, MDDiagnostic Radiology Ana Aparicio, MDGenitourinary Medical Oncology

Brian F. Chapin, MDUrology

Seungtaek Choi, MDRadiation Oncology

Paul Corn, MDGenitourinary Medical Oncology

John W. Davis, MDUrology

Farshid Dayyani, MD, PhDGenitourinary Medical Oncology

Colin Dinney, MDUrology

Robert B. Evans, PA-CUrology

William J. Graber, MDUrology

MD Anderson FacultyH. Barton Grossman, MDUrology

Karen Hoffman, MDRadiation Oncology

Eric Jonasch, MDGenitourinary Medical Oncology

Ashish Kamat, MDUrology

Jose A. Karam, MDUrology

Vikas Kundra, MD, PhDDiagnostic Radiology

Andrew Lee, MD, MPHRadiation Oncology

Surena Matin, MDUrology

Sean McGuire, MD, PhDRadiation Oncology

Randall Millikan, MD, PhDGenitourinary Medical Oncology

Lance Pagliaro, MDGenitourinary Medical Oncology

Thomas Pugh, MDRadiation Oncology

Stephen Settle, MD, PhD Radiation Oncology

Jay B. Shah, MDUrology

Arlene Siefker-Radtke, MDGenitourinary Medical Oncology

Nizar M. Tannir, MD Genitourinary Medical Oncology

John F. Ward, MDUrology

O. Lenaine Westney, MDUrology

Christopher G. Wood, MDUrology

Andrew C. von Eschenbach LectureJohn A. Libertino, MDChair, Institute of Urology Lahey Clinic Medical CenterProfessor of UrologyTufts UniversityBurlington, Massachusetts

Guest Faculty

Distinguished AlumniWassim Kassouf, MDProgram DirectorMcGill Urology ResidencyAssistant ProfessorDepartment of Surgery McGill University Health CenterMontreal, Canada

Reena W. Cherry, MS, PA-CPhysician AssistantGenitourinary Medical Oncology

Silvestina DeCoteau, RN, MSN, NEA-BCAssociate Director of Clinical NursingNursing

Deborah Hooker, RN, MSN, BC, ACNPAdvanced Practice NurseUrology

Irene A. Inguillo, BSN, RN, CURNClinical Nurse, OutpatientGU Center, Medical Oncology

Lydia T. Madsen, RN, MSN, CNSAdvanced Practice NurseGenitourinary Medical Oncology

Robert L. Massey, PhD, RN, NEA-BCAssistant ProfessorNursing

William E. Osai, RN, MSN, FNP-CAdvanced Practice NurseGenitourinary Medical Oncology

Cynthia A. Worley, BSN, RN, CWOCNWound Ostomy Continence NurseNursing

Urologic Oncology:

Nursing Advances in Clinical Practice

Educational ObjectivesAfterattendingthiseducationalactivity,participantsshouldbeableto• Describethegenitourinaryanatomyindetail;• IdentifypatientswhoarecandidatesforPSAscreeningaccordingtocurrentguidelinesandthenewPSAcontroversy;

• DiscussthetreatmentoptionsandmodalitiesofferedtonewlydiagnosedprostatecancerpatientsthroughtheMultidisciplinaryClinic;

• Identifyurothelialcancerpatientswhoaresurgicalcandidates,discusstheirpost-operativecaremanagement,anddescribeacutepost-operativecomplicationsandinterventionrationales;

• Explainthepsychologicalimpactofurinarydiversions/ostomiesanddiscussmanagement;• Discusstreatmentmodalitiesforrenaltumorobservationversussurgeryandexplaintherationaleforboth;

• DescribetherationaleandguidelinesfortheGUCancerSurvivorshipProgramandidentifythepatientbenefits.

Accreditation/Credit DesignationNursingContinuingEducationContactHourswillbeprovided.

TheUniversityofTexasMDAndersonCancerCenterisanapprovedproviderofcontinuingnursingeducationbytheTexasNursesAssociation,anaccreditedapproverbytheAmericanNursesCredentialingCenter’sCommissiononAccreditation.

MDAndersonNursingSessionFaculty

NursingSessionProgram

7:30am RegistrationandContinentalBreakfast PosterSession

8:00 Welcome and Opening Remarks DeborahHooker,RN,MSN,BC,ACNP NursingProgramCo-Chairman

8:05 Anatomical Review – Genitourinary System IreneA.Inguillo,BSN,RN,CURN8:15 Prostate Cancer Screening: Current Guidelines and

PSA Controversies DeborahHooker,RN,MSN,BC,ACNP

9:00 Multidisciplinary Prostate Cancer Clinic: What are the treatment options?

LydiaT.Madsen,RN,MSN,CNS

9:45 BreakandPosterSession

10:00 Urothelial Cancer: Candidates for Surgical Intervention Post-Operative Care and Acute Post-Operative Complications

SilvestinaDeCoteau,RN,MSN,NEA-BC;andRobertL.Massey,PhD,RN,NEA-BC

10:40 Psychological Impact and Management of Urinary

Diversion / Ostomy CynthiaA.Worley,BSN,RN,CWOCN 11:00 Renal Tumor Treatment Modalities: Surgery vs. Observation ReenaW.Cherry,MS,PA-C

11:45 Survivorship Clinic: Rationale and Benefits WilliamE.Osai,RN,MSN,FNP-C

12:15pm Closing Remarks and Evaluations SilvestinaDeCoteau,RN,MSN,NEA-BC NursingProgramCo-Chairman

Friday,November2,2012

Urologic Oncology: Nursing Advances in Clinical PracticeOn-siteregistrationopensat7:30amonFriday, November 2, 2012.Theconferencewillbeginat8:00amandendat12:15pmonFriday,November2,2012.

ThosewishingtoattendthegeneralconferencethatbeginsonFriday,November2,2012at12:45pmandendsonSaturday,November3,2012at5:30pmmustpayanadditionalfeeof$50.00.Pleaseseetheregistrationformforinstructions.

Urologic Oncology: Advances in Clinical PracticeOn-siteregistrationopensatNoononFriday, November 2, 2012.Theconferencewillbeginat12:45pmonFriday, November 2, 2012andadjournonSaturday,November3,2012at5:30pm.Advanceregistrationisencouragedasspaceandmaterialsarelimited.Pleaseseetheregistrationformforapplicablefees.

Thefullconferenceregistrationfeeincludesthetuition,syllabus,breakfasts,breaks,lunches,andreception.

The deadline for advance registration is Friday, October 19, 2012.

There are three ways to register:•Mailto:CME/ConferenceManagement–Unit1381,TheUniversityofTexasMDAndersonCancerCenter,P.O.Box301439,Houston,TX77230-1439

•Faxto:713-794-1724•On-lineatwww.mdanderson.org/conferences

We accept the following forms of payment:•Check(payablethroughU.S.banksonly)•MoneyOrder•CreditCards(MasterCard,VISA,andAmericanExpress)•Cash(on-siteregistrationonly)

Whenregisteringonlineareceipt/confirmationletterwillbeautomaticallye-mailedtothee-mailaddressyoulistontheregistrationform.Ifyouregisterbyfaxormail,areceipt/confirmationletterwillbesenttoyouwithintenworkingdaysofreceiptofyourfee.

Registration Information

Refund/CancellationPolicy Theregistrationfee,minusa$50administrativehandlingfee,isrefundableifawrittenrequestisreceivedonorbeforeOctober 19, 2012.Norefundswillbegrantedafterthatdate.Therequestforaregistrationrefundmustincludethetaxidentificationnumberofthecompanyorinstitutionifregistrationwaspaidbyacompanyorinstitutioncheck.

TheDepartmentofCME/ConferenceManagementreservestherighttocancelactivitiespriortothescheduleddate,iflowenrollmentorothercircumstancesmakeitnecessary.Eachregistrantwillbenotifiedbymail,e-mail,oratthephoneorfaxnumbersgivenontheregistrationform.Incaseofactivitycancellation,theliabilityoftheDepartmentofCME/ConferenceManagementislimitedtotheregistrationfee.CME/ConferenceManagementwillrefundthefullregistrationfee.

TheDepartmentofCME/ConferenceManagementreservestherighttolimitthenumberofparticipantsinaprogramandisnotresponsibleforanyexpensesincurredbyanindividualwhoseregistrationisnotconfirmedandforwhomspaceisnotavailable.

SpecialAssistanceContacttheDepartmentofCME/ConferenceManagementat713-792-2223ortollfreeat866-849-5866ifyouhaveanyspecialdietaryorADAaccommodationneeds.

Accommodations• AblockofroomshasbeenreservedforconferenceattendeesattheHouston Marriott at the Texas Medical Center,6580FanninStreet,Houston,Texas.• Earlyhotelreservationissuggested.Tomakereservations,pleasecallMarriott Reservationsat800-228-9290andidentifyyourselfaspartoftheUrologic

Oncology MD Anderson Room BlockgroupstayingattheHoustonMarriottattheTexasMedicalCenter.

• Thespecialmeetingrateis$112.00singleordoubleoccupancy.Pleaseadd17% TexasStateandlocaltaxes.ReservationsanddepositsreceivedafterOctober 18, 2012willbeconfirmedifspaceisavailableandatcurrenthotelpublishedguestroomrates.

Please let us know what specific topics, issues or questions you wish to see addressed or emphasized in this activity. Fax or e-mail CME/Conference Management. All responses will be forwarded to the Program Chairs for consideration.

GroundTransportation (prices are subject to change and variable depending on location of conference)• Houstonisservedbytwoairports,GeorgeBushIntercontinental(IAH)andWilliamP.Hobby(HOU).

• Taxicabsareavailableatanestimatedcostof$50-60,toorfromWilliamP.HobbyAirportorGeorgeBushIntercontinentalAirport.

• SuperShuttleoperatesashuttlebusbetweenGeorgeBushIntercontinentalAirportandtheHoustonMarriottattheTexasMedicalCenterfor$27one-wayand$54round-trip.Formoreinformation,call713-523-8888ortoll-freeat800-258-3826oron-lineatwww.supershuttle.com.

• SuperShuttleoperatesashuttlebusbetweenWilliamP.HobbyAirportandtheHoustonMarriottattheTexasMedicalCenterfor$24one-wayand$48round-trip.Formoreinformation,call713-523-8888ortoll-freeat800-258-3826oron-lineatwww.supershuttle.com.

The University of Texas MD Anderson Cancer Center has implemented a process whereby everyone who is in a position to control the content of an educational activity must disclose all relevant financial relationships with any commercial interest that could potentially affect the information presented. MD Anderson also requires that all faculty disclose any unlabeled use or investigational use (not yet approved for any purpose) of pharmaceutical and medical device products. Specific disclosure will be made to the participants prior to the educational activity.

Agendas are subject to change because we are always striving to improve the quality of your educational experience. MD Anderson may substitute faculty with comparable expertise on rare occasions necessitated by illness, schedule conflicts, and so forth.

Photographing, audio taping and videotaping are prohibited.

CON

FERE

NCE

REG

ISTR

ATIO

N -

0592

7th

Urol

ogic

Onco

logy

: Adv

ance

s in

Clin

ical

Pra

ctice

— N

ovem

ber 2

-3, 2

012

Nursi

ng Se

ssion

Urol

ogic

Onco

logy

: Nur

sing A

dvan

ces i

n Cl

inic

al P

ract

ice —

Nov

embe

r 2, 2

012

Last

Nam

e

Fi

rst

M

I

H

ighe

st D

egre

e

Depa

rtmen

t (in

clud

e bo

x no

.)

Spe

cial

ty

Inst

itutio

n

Phy

sici

an:

o

Yes

oN

oSt

reet

C

ity

S

tate

/For

eign

Cou

ntry

/Zip

or M

ail C

ode

Dayt

ime

Phon

e (w

ith a

rea

code

)

Ce

ll Ph

one

(with

are

a co

de)

Fax

(with

are

a co

de)

E-m

ail A

ddre

ss

E

mer

genc

y Co

ntac

t

P

hone

(with

are

a co

de)

Char

ge th

e fo

llow

ing:

o

VISA

oM

aste

rCar

d

o

Amer

ican

Exp

ress

Cred

it Ca

rd N

umbe

r or M

D An

ders

on In

terd

epar

tmen

tal T

rans

fer (

IDT)

No.

Expi

ratio

n Da

te

Cred

it Ca

rd H

olde

r Nam

e (F

irst/L

ast)

C

redi

t Car

d Ho

lder

Bill

ing

Addr

ess

& Z

IP C

ode

Auth

orize

d Si

gnat

ure

REQU

IRED

for c

redi

t car

d or

IDT

MD

Ande

rson

Em

ploy

ee ID

No.

(REQ

UIRE

D)

IDT

Appr

over

Nam

e (F

irst/L

ast)

plea

se p

rint

IDT

Appr

over

E-m

ail

THIS

IS N

OT A

SEL

F-M

AILE

R - A

ddre

ss to

: 7t

h Ur

olog

ic O

ncol

ogy:

Adv

ance

s in

Clin

ical

Pra

ctic

e

Nur

sing

Ses

sion

Urol

ogic

Onc

olog

y: N

ursi

ng A

dvan

ces

in

Clin

ical

Pra

ctic

eDe

partm

ent o

f CM

E/Co

nfer

ence

Man

agem

ent

Unit

1381

The

Univ

ersi

ty o

f Tex

as M

D An

ders

on C

ance

r Cen

ter

PO B

ox 3

0143

9, H

oust

on, T

X 77

230-

1439

or fa

x to

713

-794

-172

4 M

ake

chec

k or

mon

ey o

rder

pay

able

to:

The

Univ

ersi

ty o

f Tex

as M

D An

ders

on C

ance

r Cen

ter

GENE

RAL C

ONFE

RENC

E RE

GIST

RATI

ON FE

ESPh

ysic

ians

1 P

ostm

arke

d be

fore

Oct

. 19,

2012

.......

........

.$25

0.00

1 P

ostm

arke

d af

ter O

ct. 1

9, 20

12 ...

........

........

$300

.00

Stud

ents

/Tra

inee

s/PA

s1 P

ostm

arke

d be

fore

Oct

. 19,

2012

.......

........

.$55

.00

1 P

ostm

arke

d af

ter O

ct. 1

9, 20

12 ...

........

........

$80.0

0

NURS

E SE

SSIO

N RE

GIST

RATI

ON FE

ES 1

Pos

tmar

ked

befo

re O

ct. 1

9, 20

12 ...

........

.....$

45.00

1

Pos

tmar

ked

afte

r Oct

. 19,

2012

.......

........

....$5

5.00

Gene

ral C

onfe

renc

e Fe

e - N

urse

s 1

.......

........

........

........

........

........

........

........

........

.....$

50.00

Depa

rtmen

t of C

ME/

Conf

eren

ce M

anag

emen

t - U

nit 1

381

The

Univ

ersi

ty o

f Tex

as M

D An

ders

on C

ance

r Cen

ter

#176

700/

3007

0592

PO B

ox 3

0143

9Ho

usto

n, T

X 77

230-

1439

Non

-Pro

fit O

rg.

U.S.

Pos

tage

PAID

Perm

it N

o. 7

052

Hous

ton,

TX